In vitro cytotoxicity assay to evaluate the toxicity of an electrophilic reactive metabolite using glutathione-depleted rat primary cultured hepatocytes

被引:12
作者
Fujimoto, Kazunori [1 ]
Kishino, Hiroyuki [1 ]
Yamoto, Takashi [1 ]
Manabe, Sunao [2 ]
Sanbuissho, Atsushi [1 ]
机构
[1] Daiichi Sankyo Co Ltd, Med Safety Res Labs, R&D Div, Shizuoka 4370065, Japan
[2] Daiichi Sankyo Co Ltd, Global Project Management Dept, R&D Div, Tokyo 1408710, Japan
关键词
Cellular glutathione depletion; Rat primary cultured hepatocyte; Electrophilic reactive metabolite; Cytotoxic sensitivity gap; Idiosyncratic drug toxicity; IDIOSYNCRATIC DRUG-REACTIONS; HEPATOTOXICITY;
D O I
10.1016/j.cbi.2010.09.012
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Glutathione plays an important role as not only a scavenger of reactive oxygen species but also in the conjugation or detoxification of electrophilic reactive metabolites, which has been thought to be one of the causes for idiosyncratic drug toxicity (IDT). Therefore, toxic responses to the reactive metabolites have been expected to be expressed more strongly in a glutathione-depleted condition. In the present study, we attempted to establish an in vitro cytotoxicity assay method to evaluate the toxicity of the reactive metabolite using rat primary cultured hepatocytes with cellular glutathione depletion by L-buthionine-S,R-sulfoximine. Also, we investigated whether the IDT risk is predictable by comparing the cytotoxic sensitivity between glutathione-depleted hepatocytes and untreated hepatocytes. Consequently, 10 drugs of 42 approved drugs, which were classified into 4 IDT categories (Withdrawn, Black box warning, Warning, and Safe), demonstrated higher cytotoxic sensitivity in the glutathione-depleted hepatocytes. Furthermore, a correlation was observed between the incidence of drugs with higher cytotoxic sensitivity in the glutathione-depleted hepatocytes and the IDT risk. The incidence was 50% in the Withdrawn category, 38% in the Black box warning category, 22% in the Warning category, and 8% in the Safe category. These results suggest that the IDT risk of some drugs may be predicted by comparing the cytotoxic sensitivity between them. Additionally, this method may be useful as a screening in the early stage of drug development where leads/candidates are optimized. (C) 2010 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:404 / 411
页数:8
相关论文
共 28 条
[1]  
BAKER DD, 2009, TOXICOLOGIST, V108, P87
[2]   Can In Vitro Metabolism-Dependent Covalent Binding Data Distinguish Hepatotoxic from Nonhepatotoxic Drugs? An Analysis Using Human Hepatocytes and Liver S-9 Fraction [J].
Bauman, Jonathon N. ;
Kelly, Joan M. ;
Tripathy, Sakambari ;
Zhao, Sabrina X. ;
Lam, Wing W. ;
Kalgutkar, Amit S. ;
Obach, R. Scott .
CHEMICAL RESEARCH IN TOXICOLOGY, 2009, 22 (02) :332-340
[3]   Synergistic drug-cytokine induction of hepatocellular death as an in vitro approach for the study of inflammation-associated idiosyncratic drug hepatotoxicity [J].
Cosgrove, Benjamin D. ;
King, Bracken M. ;
Hasan, Maya A. ;
Alexopoulos, Leonidas G. ;
Farazi, Paraskevi A. ;
Hendriks, Bart S. ;
Griffith, Linda G. ;
Sorger, Peter K. ;
Tidor, Bruce ;
Xu, Jinghai J. ;
Lauffenburger, Douglas A. .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 2009, 237 (03) :317-330
[4]   Dansyl glutathione as a trapping agent for the quantitative estimation and identification of reactive metabolites [J].
Gan, JP ;
Harper, TW ;
Hsueh, MM ;
Qu, QL ;
Humphreys, WG .
CHEMICAL RESEARCH IN TOXICOLOGY, 2005, 18 (05) :896-903
[5]   RE-EVALUATION OF PROTEIN-BOUND GLUTATHIONE IN RAT-LIVER [J].
HIGASHI, T ;
FURUKAWA, M ;
HIKITA, K ;
NARUSE, A ;
TATEISHI, N ;
SAKAMOTO, Y .
JOURNAL OF BIOCHEMISTRY, 1985, 98 (06) :1661-1667
[6]   Acetaminophen-induced hepatotoxicity [J].
James, LP ;
Mayeux, PR ;
Hinson, JA .
DRUG METABOLISM AND DISPOSITION, 2003, 31 (12) :1499-1506
[7]   Idiosyncratic drug hepatotoxicity [J].
Kaplowitz, N .
NATURE REVIEWS DRUG DISCOVERY, 2005, 4 (06) :489-499
[8]  
Kato R., 1996, JPN J CLIN PHARM THE, V27, P759, DOI [DOI 10.3999/JSCPT.27.759, 10.3999/jscpt.27.759]
[9]   Idiosyncratic drug reactions: the reactive metabolite syndromes [J].
Knowles, SR ;
Uetrecht, J ;
Shear, NH .
LANCET, 2000, 356 (9241) :1587-1591
[10]  
KOCAREK TA, 1993, MOL PHARMACOL, V43, P328